Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PROCEPT BioRobotics (PRCT)
NASDAQ:PRCT
Holding PRCT?
Track your performance easily
PRCT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$31.57 - $103.81
Previous Close$93.57
Volume433.63K
Average Volume (3M)912.34K
Market Cap
$5.09B
Enterprise Value$4.97B
Total Cash (Recent Filing)$196.76M
Total Debt (Recent Filing)$80.64M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Mar 04, 2025EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.95
Shares Outstanding52,183,184
10 Day Avg. Volume834,501
30 Day Avg. Volume912,344
Standard Deviation0.16
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)20.25
Price to Sales (P/S)23.22
Price to Cash Flow (P/CF)-63.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue24.89
Enterprise Value/Gross Profit70.00
Enterprise Value/Ebitda-52.06
Forecast
1Y Price Target
$92.86Price Target Upside0.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
PROCEPT BioRobotics News
Bulls Say, Bears Say
Bulls Say
Innovative Product LaunchPRCT's new robot Hydros represented 80% of the US systems sold in Q3, indicating strong future demand.
Regulatory MilestonesPRCT received FDA approval to initiate a pivotal study of Aquablation in prostate cancer, representing an incremental positive for the stock.
Revenue GrowthPRCT's revenue of approximately $58.4 million exceeded expectations, showcasing strong system placements and confidence in higher system ASPs.
Bears Say
Growth ConcernsDespite higher ASPs, there are concerns about utilization, which could impact future growth.
Market ChallengesThere are reservations on initial demand into 2025 as management has yet to identify specific incremental clinical benefits with HYDROS coupled with the continued market segmentation by prostate size.
ValuationThe current valuation of PRCT offers limited upside compared to its peers in the high-growth Medical Technology sector.
---
Ownership Overview
9.95% Insiders
36.05% Mutual Funds
23.73% Other Institutional Investors
14.71% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRCT FAQ
What was PROCEPT BioRobotics’s price range in the past 12 months?
PROCEPT BioRobotics lowest stock price was $31.57 and its highest was $103.81 in the past 12 months.
What is PROCEPT BioRobotics’s market cap?
Currently, no data Available
When is PROCEPT BioRobotics’s upcoming earnings report date?
PROCEPT BioRobotics’s upcoming earnings report date is Mar 04, 2025 which is in 101 days.
How were PROCEPT BioRobotics’s earnings last quarter?
PROCEPT BioRobotics released its earnings results on Oct 28, 2024. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.489 by $0.089.
Is PROCEPT BioRobotics overvalued?
According to Wall Street analysts PROCEPT BioRobotics’s price is currently Undervalued.
Does PROCEPT BioRobotics pay dividends?
PROCEPT BioRobotics does not currently pay dividends.
What is PROCEPT BioRobotics’s EPS estimate?
PROCEPT BioRobotics’s EPS estimate is -$0.34.
How many shares outstanding does PROCEPT BioRobotics have?
PROCEPT BioRobotics has 54,394,722 shares outstanding.
What happened to PROCEPT BioRobotics’s price movement after its last earnings report?
PROCEPT BioRobotics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.489. Following the earnings report the stock price went up 32.325%.
Which hedge fund is a major shareholder of PROCEPT BioRobotics?
Among the largest hedge funds holding PROCEPT BioRobotics’s share is Driehaus Capital Management LLC. It holds PROCEPT BioRobotics’s shares valued at 28M.
---
PROCEPT BioRobotics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.86 (0.17% Upside)
$92.86 (0.17% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $26.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 11.4%
Last 30 Days ▲ 11.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
183.03%
12-Months-Change
Fundamentals
Return on Equity
-37.02%
Trailing 12-Months
Asset Growth
-11.16%
Trailing 12-Months
Company Description
PROCEPT BioRobotics
PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology.
---
PRCT Company Deck
---
PRCT Earnings Call
Q3 2024
0:00 / 0:00
---
PRCT Stock 12 Month Forecast
Average Price Target
$92.86
▲(0.17% Upside)
Technical Analysis
Best Analysts Covering PRCT
1 Year
1 Year Success Rate
17/19 ratings generated profit
1 Year Average Return
+69.29%
assigned a buy rating 24 days ago
Copying Richard Newitter's trades and holding each position for 1 Year would result in 89.47% of your transactions generating a profit, with an average return of +69.29% per trade.
---